Skip to main content
. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409

Fig 2. Patient disposition in DYNAMO 2.

Fig 2

MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.